News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,086 Results
Type
Article (2435)
Company Profile (39)
Press Release (35612)
Section
Business (14117)
Career Advice (77)
Deals (2077)
Drug Delivery (8)
Drug Development (4100)
Employer Resources (10)
FDA (431)
Job Trends (761)
News (20133)
Policy (1053)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (143)
Allergies (4)
Alliances (3468)
ALS (4)
Alzheimer's disease (45)
Antibody-drug conjugate (ADC) (14)
Approvals (432)
Artificial intelligence (9)
Autoimmune disease (2)
Automation (1)
Bankruptcy (12)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (12)
Biotechnology (29)
Bladder cancer (6)
Brain cancer (5)
Breast cancer (17)
Cancer (129)
Cardiovascular disease (4)
Career advice (64)
Career pathing (1)
CAR-T (14)
Cell therapy (41)
Cervical cancer (2)
Clinical research (3169)
Collaboration (88)
Compensation (44)
COVID-19 (180)
CRISPR (7)
C-suite (26)
Cystic fibrosis (2)
Data (102)
Denatured (3)
Depression (3)
Diabetes (9)
Diagnostics (463)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (13)
Drug pricing (7)
Duchenne muscular dystrophy (12)
Earnings (4230)
Editorial (3)
Employer branding (1)
Employer resources (8)
Events (6005)
Executive appointments (87)
FDA (474)
Featured Employer (3)
Funding (74)
Gene editing (14)
Gene therapy (17)
GLP-1 (60)
Government (149)
Healthcare (704)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (15)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (986)
IRA (7)
Job creations (290)
Job search strategy (62)
Kidney cancer (4)
Labor market (3)
Layoffs (36)
Leadership (1)
Legal (212)
Liver cancer (5)
Lung cancer (15)
Lymphoma (3)
Management (4)
Manufacturing (18)
MASH (4)
Medical device (306)
Medtech (306)
Mergers & acquisitions (1150)
Metabolic disorders (32)
Multiple sclerosis (6)
Neurodegenerative disease (8)
Neuropsychiatric disorders (3)
Neuroscience (88)
NextGen: Class of 2025 (352)
Non-profit (153)
Northern California (332)
Now hiring (4)
Obesity (15)
Opinion (15)
Ovarian cancer (10)
Pain (8)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (1)
Patents (19)
Patient recruitment (2)
Peanut (1)
People (5632)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase I (1370)
Phase II (1588)
Phase III (844)
Pipeline (71)
Podcasts (4)
Policy (13)
Postmarket research (30)
Preclinical (589)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (21)
Real estate (419)
Recruiting (5)
Regulatory (802)
Reports (6)
Research institute (142)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (24)
Series B (5)
Service/supplier (2)
Sickle cell disease (1)
Southern California (338)
Special edition (1)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (488)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1630)
Vaccines (28)
Venture capitalists (7)
Webinars (2)
Weight loss (11)
Women's health (1)
Worklife (1)
Date
Today (16)
Last 7 days (67)
Last 30 days (234)
Last 365 days (2568)
2025 (631)
2024 (2612)
2023 (2858)
2022 (3750)
2021 (4048)
2020 (3473)
2019 (2064)
2018 (1555)
2017 (1795)
2016 (1625)
2015 (1833)
2014 (1370)
2013 (1190)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (14)
Asia (1860)
Australia (298)
California (773)
Canada (130)
China (38)
Colorado (19)
Connecticut (10)
Delaware (3)
Europe (3805)
Florida (43)
Georgia (5)
Idaho (3)
Illinois (14)
India (1)
Indiana (30)
Japan (7)
Kansas (12)
Maryland (24)
Massachusetts (285)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (2)
New Hampshire (2)
New Jersey (66)
New York (45)
North Carolina (88)
Northern California (332)
Ohio (25)
Oklahoma (2)
Oregon (4)
Pennsylvania (45)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (338)
Tennessee (2)
Texas (66)
Utah (2)
Virginia (6)
Washington D.C. (1)
Washington State (44)
Wisconsin (6)
38,086 Results for "vedanta biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
January 23, 2025
·
5 min read
Press Releases
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
January 27, 2025
·
10 min read
Genetown
Vedanta Biosciences to Present at Upcoming Investor Conferences - April 29, 2024
Vedanta Biosciences today announced that members of its executive team will participate at the following investor conferences.
April 29, 2024
·
1 min read
Drug Development
Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study.
May 21, 2024
·
5 min read
Genetown
Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference
Vedanta Biosciences announced that management will host investor meetings at the Leerink Partners 2024 Global Biopharma Conference being held in Miami, FL from Monday, March 11 through Wednesday, March 13, 2024.
March 6, 2024
·
1 min read
News
Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
October 16, 2024
·
5 min read
Genetown
Vedanta Biosciences to Participate at Upcoming Investor Conferences
Vedanta Biosciences today announced that members of its executive team will participate at the following investor conferences.
October 5, 2023
·
1 min read
Drug Development
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
PureTech Health plc noted that its Founded Entity, Vedanta Biosciences announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study of VE303, which is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection.
May 21, 2024
·
8 min read
Genetown
Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings
Vedanta Biosciences today announced that the Opposition Division of the European Patent Office (EPO) has fully upheld Vedanta’s foundational patents EP3178483B1, EP3552613B1, and EP3539548B1 (the “Honda patents”) in oral opposition proceedings held in Munich over the course of three weeks.
November 28, 2023
·
3 min read
Genetown
Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposium
Vedanta Biosciences today announced that management will host investor meetings at the Wells Fargo Virtual Private Biotech Symposium being held on Wednesday, November 1, 2023.
October 25, 2023
·
1 min read
1 of 3,809
Next
